Department of Thyroid Surgery, The Second hospital of Jilin University, Changchun, Jilin, China.
Front Endocrinol (Lausanne). 2023 Jul 19;14:1146955. doi: 10.3389/fendo.2023.1146955. eCollection 2023.
This study aimed to systematically review research on cinacalcet and secondary hyperparathyroidism (SHPT) using machine learning-based statistical analyses.
Publications indexed in the Web of Science Core Collection database on Cinacalcet and SHPT published between 2000 and 2022 were retrieved. The R package "Bibliometrix," VOSviewer, CiteSpace, meta, and latent Dirichlet allocation (LDA) in Python were used to generate bibliometric and meta-analytical results.
A total of 959 articles were included in our bibliometric analysis. In total, 3753 scholars from 54 countries contributed to this field of research. The United States, Japan, and China were found to be among the three most productive countries worldwide. Three Japanese institutions (Showa University, Tokai University, and Kobe University) published the most articles on Cinacalcet and SHPT. Fukagawa, M.; Chertow, G.M.; Goodman W.G. were the three authors who published the most articles in this field. Most articles were published in , , and . Research on Cinacalcet and SHPT has mainly included three topics: 1) comparative effects of various treatments, 2) the safety and efficacy of cinacalcet, and 3) fibroblast growth factor-23 (FGF-23). Integrated treatments, cinacalcet use in pediatric chronic kidney disease, and new therapeutic targets are emerging research hotspots. Through a meta-analysis, we confirmed the effects of Cinacalcet on reducing serum PTH ( = -0.56, 95% = -0.76 to -0.37, = 0.001) and calcium ( = -0.93, 95% = -1.21to -0.64, = 0.001) and improving phosphate ( = 0.17, 95% = -0.33 to -0.01, = 0.033) and calcium-phosphate product levels ( = -0.49, 95% = -0.71 to -0.28, = 0.001); we found no difference in all-cause mortality ( = 0.97, 95% = 0.90 to 1.05, = 0.47), cardiovascular mortality ( = 0.69, 95% = 0.36 to 1.31, = 0.25), and parathyroidectomy ( = 0.36, 95% = 0.09 to 1.35, = 0.13) between the Cinacalcet and non-Cinacalcet users. Moreover, Cinacalcet was associated with an increased risk of nausea ( = 2.29, 95% = 1.73 to 3.05, = 0.001), hypocalcemia ( = 4.05, 95% = 2.33 to 7.04, = 0.001), and vomiting ( = 1.90, 95% = 1.70 to 2.11, = 0.001).
The number of publications indexed to Cinacalcet and SHPT has increased rapidly over the past 22 years. Literature distribution, research topics, and emerging trends in publications on Cinacalcet and SHPT were analyzed using a machine learning-based bibliometric review. The findings of this meta-analysis provide valuable insights into the efficacy and safety of cinacalcet for the treatment of SHPT, which will be of interest to both clinical and researchers.
本研究旨在通过基于机器学习的统计分析，系统地回顾关于西那卡塞和继发性甲状旁腺功能亢进症（SHPT）的研究。
检索了 2000 年至 2022 年期间在 Web of Science 核心合集数据库中索引的关于西那卡塞和 SHPT 的出版物。使用 R 包“Bibliometrix”、VOSviewer、CiteSpace、meta 和 Python 中的潜在狄利克雷分配（LDA）生成文献计量和元分析结果。
我们的文献计量分析共纳入 959 篇文章。来自 54 个国家的 3753 位学者为该领域的研究做出了贡献。美国、日本和中国是全球三个最具生产力的国家。三所日本机构（昭和大学、东海大学和神户大学）发表了最多关于西那卡塞和 SHPT 的文章。Fukagawa，M.；Chertow，G.M.；Goodman W.G.是该领域发表文章最多的三位作者。大多数文章发表在《柳叶刀》、《新英格兰医学杂志》和《美国肾脏病杂志》上。关于西那卡塞和 SHPT 的研究主要包括三个主题：1）各种治疗方法的比较效果，2）西那卡塞的安全性和疗效，3）成纤维细胞生长因子 23（FGF-23）。综合治疗、西那卡塞在儿科慢性肾脏病中的应用以及新的治疗靶点是新兴的研究热点。通过一项荟萃分析，我们证实了西那卡塞在降低血清甲状旁腺激素（ = -0.56，95% = -0.76 至 -0.37， = 0.001）和钙（ = -0.93，95% = -1.21 至 -0.64， = 0.001）以及改善磷（ = 0.17，95% = -0.33 至 -0.01， = 0.033）和钙磷乘积水平（ = -0.49，95% = -0.71 至 -0.28， = 0.001）方面的作用；我们发现全因死亡率（ = 0.97，95% = 0.90 至 1.05， = 0.47）、心血管死亡率（ = 0.69，95% = 0.36 至 1.31， = 0.25）和甲状旁腺切除术（ = 0.36，95% = 0.09 至 1.35， = 0.13）在西那卡塞和非西那卡塞使用者之间没有差异。此外，西那卡塞与恶心（ = 2.29，95% = 1.73 至 3.05， = 0.001）、低钙血症（ = 4.05，95% = 2.33 至 7.04， = 0.001）和呕吐（ = 1.90，95% = 1.70 至 2.11， = 0.001）的风险增加相关。
过去 22 年来，索引到西那卡塞和 SHPT 的出版物数量迅速增加。本研究通过基于机器学习的文献计量学综述，分析了西那卡塞和 SHPT 文献的分布、研究主题和新兴趋势。这项荟萃分析的结果为西那卡塞治疗 SHPT 的疗效和安全性提供了有价值的见解，这将引起临床和研究人员的兴趣。
